These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 9354694)
21. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. Gribben JG; Freedman AS; Neuberg D; Roy DC; Blake KW; Woo SD; Grossbard ML; Rabinowe SN; Coral F; Freeman GJ N Engl J Med; 1991 Nov; 325(22):1525-33. PubMed ID: 1944436 [TBL] [Abstract][Full Text] [Related]
22. Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Gribben JG; Saporito L; Barber M; Blake KW; Edwards RM; Griffin JD; Freedman AS; Nadler LM Blood; 1992 Aug; 80(4):1083-9. PubMed ID: 1498325 [TBL] [Abstract][Full Text] [Related]
23. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies. Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988 [TBL] [Abstract][Full Text] [Related]
24. Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation. Hardingham JE; Kotasek D; Sage RE; Dobrovic A; Gooley T; Dale BM Bone Marrow Transplant; 1993 Jan; 11(1):15-20. PubMed ID: 8381694 [TBL] [Abstract][Full Text] [Related]
25. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up. Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845 [TBL] [Abstract][Full Text] [Related]
26. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Delage R; Soiffer RJ; Dear K; Ritz J Blood; 1991 Nov; 78(10):2759-67. PubMed ID: 1824268 [TBL] [Abstract][Full Text] [Related]
27. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348 [TBL] [Abstract][Full Text] [Related]
28. Detection of clonal CD34+19+ progenitors in bone marrow of BCL2-IgH-positive follicular lymphoma patients. Macintyre EA; Belanger C; Debert C; Canioni D; Turhan AG; Azagury M; Hermine O; Varet B; Flandrin G; Schmitt C Blood; 1995 Dec; 86(12):4691-8. PubMed ID: 8541563 [TBL] [Abstract][Full Text] [Related]
29. High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma. McCann JC; Kanteti R; Shilepsky B; Miller KB; Sweet M; Schenkein DP Biol Blood Marrow Transplant; 1996 Feb; 2(1):37-43. PubMed ID: 9078353 [TBL] [Abstract][Full Text] [Related]
30. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting. Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252 [TBL] [Abstract][Full Text] [Related]
31. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement. Morishima Y; Miyamura K; Kojima S; Ueda R; Morishita Y; Sao H; Tanimoto M; Ohno R; Sobue R; Hirano M Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550 [TBL] [Abstract][Full Text] [Related]
32. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma. Galimberti S; Marasca R; Caracciolo F; Fazzi R; Papineschi F; Benedetti E; Guerrini F; Morabito F; Oliva E; Di Renzo N; Federico M; Petrini M; Torelli G; Bone Marrow Transplant; 2002 Apr; 29(7):581-7. PubMed ID: 11979307 [TBL] [Abstract][Full Text] [Related]
33. Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD). Olsson K; Gerard CJ; Zehnder J; Jones C; Ramanathan R; Reading C; Hanania EG Leukemia; 1999 Nov; 13(11):1833-42. PubMed ID: 10557059 [TBL] [Abstract][Full Text] [Related]
34. Detection of residual leukemia by the polymerase chain reaction and sequence-specific oligonucleotide probe hybridization after allogeneic bone marrow transplantation for AKR leukemia: a murine model for minimal residual disease. Drobyski WR; Baxter-Lowe LA; Truitt RL Blood; 1993 Jan; 81(2):551-9. PubMed ID: 8422472 [TBL] [Abstract][Full Text] [Related]
35. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498 [TBL] [Abstract][Full Text] [Related]
36. Rearranged immunoglobulin light chain genes as minimal residual disease markers in intermediate- and high-grade malignant B cell non-Hodgkin's lymphoma. Hoogeveen-Westerveld M; Hupkes PE; Doekharan D; Dorssers LC; van't Veer MB; van Belzen N Leukemia; 1998 Nov; 12(11):1810-6. PubMed ID: 9823958 [TBL] [Abstract][Full Text] [Related]
37. PCR-positivity in harvested bone marrow predicts relapse after transplantation with autologous purged bone marrow in children in second remission of precursor B-cell acute leukaemia. Vervoordeldonk SF; Merle PA; Behrendt H; Steenbergen EJ; van den Berg H; van Wering ER; von dem Borne AE; van der Schoot CE; van Leeuwen EF; Slaper-Cortenbach IC Br J Haematol; 1997 Feb; 96(2):395-402. PubMed ID: 9029032 [TBL] [Abstract][Full Text] [Related]
38. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Knechtli CJ; Goulden NJ; Hancock JP; Harris EL; Garland RJ; Jones CG; Grandage VL; Rowbottom AW; Green AF; Clarke E; Lankester AW; Potter MN; Cornish JM; Pamphilon DH; Steward CG; Oakhill A Br J Haematol; 1998 Aug; 102(3):860-71. PubMed ID: 9722317 [TBL] [Abstract][Full Text] [Related]
39. Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma. Andersen NS; Donovan JW; Zuckerman A; Pedersen L; Geisler C; Gribben JG Exp Hematol; 2002 Jul; 30(7):703-10. PubMed ID: 12135667 [TBL] [Abstract][Full Text] [Related]
40. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang. Gimenez E; Chauvet M; Rabin L; Puteaud I; Duley S; Hamaidia S; Bruder J; Rolland-Neyret V; Le Gouill S; Tournilhac O; Voog E; Maisonneuve H; Jacob MC; Leroux D; Béné MC; Formisano-Tréziny C; Gabert J; Gressin R; Callanan MB Br J Haematol; 2012 Jul; 158(2):186-197. PubMed ID: 22626453 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]